Skip to main content
. 2010 Aug 5;172(5):578–590. doi: 10.1093/aje/kwq175

Table 4.

Association Between Use of Nonaspirin NSAIDs and Prostate Cancer in a Population-based Case-Control Study in King County, Washington, 2002–2005

NSAID Use (Nonaspirin) Casesa (n = 998)
 Controlsa (n = 941)
 Odds Ratiob 95% CI Odds Ratioc 95% CI
No. % No. %
Ever used
    Never 786 78.8 743 79.0 1.00 Referent 1.00 Referent
    Ever 212 21.2 198 21.0 1.02 0.82, 1.27 1.05 0.84, 1.32
        Daily NSAID 98 11.1 73 8.9 1.27 0.92, 1.75 1.32 0.95, 1.83
        Cox-2 specifice 38 4.6 26 3.4 1.39 0.84, 2.32 1.47 0.88, 2.47
Age at first use, years
    Nonuser 786 79.0 743 79.5 1.00 Referent 1.00 Referent
    <50 101 10.2 88 9.4 1.13 0.83, 1.54 1.19 0.86, 1.63
    50–64 81 8.1 78 8.3 0.96 0.69, 1.34 0.97 0.70, 1.36
    ≥65 27 2.7 26 2.8 0.95 0.54, 1.67 0.99 0.56, 1.76
Recency of use
    Nonuser 786 78.8 743 79.0 1.00 Referent 1.00 Referent
    Former user 66 6.6 56 6.0 1.14 0.78, 1.64 1.23 0.85, 1.80
    Current userf 146 14.6 142 15.1 0.97 0.76, 1.25 0.99 0.76, 1.28
Duration of use, years
    Continuous user 0.99 0.98, 1.01 0.99 0.98, 1.01
    Nonuser 786 78.8 743 79.1 1.00 Referent 1.00 Referent
    ≤5 111 11.1 99 10.5 1.07 0.80, 1.42 1.11 0.83, 1.49
    >5 100 10.0 97 10.3 0.98 0.73, 1.32 1.01 0.74, 1.37
Time since first use, years
    Nonuser 786 79.0 743 79.5 1.00 Referent 1.00 Referent
    0.1–4.9 67 6.7 68 7.3 0.92 0.65, 1.32 0.96 0.67, 1.37
    5–9.9 52 5.2 40 4.3 1.25 0.82, 1.92 1.26 0.82, 1.95
    ≥10 90 9.0 84 9.0 1.02 0.75, 1.40 1.07 0.78, 1.48

Abbreviations: CI, confidence interval; Cox-2, cyclooxygenase 2; NSAID, nonsteroidal antiinflammatory drug.

a

Three cases and 1 control who did not know whether they had ever used nonaspirin NSAIDs were excluded from all analyses.

b

Adjusted for age at reference date.

c

Adjusted for age at reference date, race, and prostate cancer screening within 5 years before reference date.

d

“Ever use” was defined as use of nonaspirin NSAIDs at least once per week for a period of 3 months or longer.

e

Use of Bextra (Pfizer, Inc., New York, NY), Celebrex (Pfizer), and/or Vioxx (Merck & Co., Inc., Whitehouse Station, NJ) at least once per week for 3 months or longer.

f

“Current use” is defined as use within the year prior to reference date.